MedTrace Logo

Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

NCT06080399 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2026-05-12

No results posted yet for this study

Summary

Since our previous study has shown that some personality dimensions were associated with Quality of Life (QoL) amelioration after Deep Brain Stimulation (DBS) in Parkinson's disease (PD), the investigators aim to evaluate the impact of personality dimensions on therapeutic response after another second-line treatment: the continuous subcutaneous apomorphine infusion (CSAI). Moreover, the investigators would like to evaluate the potential evolution of personality dimensions through CSAI. The investigators also aim to evaluate other bio-psycho-social factors (representations of the disease, ways of copying and social support) influence on QoL amelioration after DBS.

Conditions

  • Parkinson Disease

Interventions

OTHER

Continuous subcutaneous apomorphine infusion (CSAI)

the CSAI proposed in the usual healthcare pathway of each PD patients included

Sponsors & Collaborators

  • ELIVIE France

    collaborator UNKNOWN

  • EVER Pharma France SAS

    collaborator UNKNOWN

  • NHC SAS, France

    collaborator UNKNOWN

  • Orkyn'

    collaborator INDUSTRY

  • ETPARK Association, Toulouse, France

    collaborator UNKNOWN

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • CHRISTINE BREFEL COURBON · University Hospital, Toulouse

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2026-03-30
Completion
2026-03-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06080399 on ClinicalTrials.gov